Table 3. Ocular characteristics, recurrences, and complications of patients with ocular involvement from toxoplasmosis, Brazil*.
| Age, y/sex |
Baseline eye examination |
Follow-up findings |
Complications |
Last VA, mo; result |
||
|---|---|---|---|---|---|---|
| RC |
Right |
Left |
||||
| 38/M† |
Bilateral |
VA 0.0; SLE, AV cells and AC cells (0.5+/4+); FE, multifocal PR and peripheral large FNR |
VA 0.0; SLE, AV cells; FE, PR |
1 OD recurrence; month 2, satellite active lesion |
None |
21; 0.0 OU |
| 47/M† |
Bilateral |
VA 0.2; SLE, AV cells;FE, peripheral large FNR |
VA 0.0; SLE, AV cells; FE, multiple peripheral large FNR |
1 OD recurrence; month 22, new peripheral scar |
Month 22, epiretinal membrane OD |
34; 0.0 OU |
| 40/M† | Bilateral | VA 0.0; SLE, AV cells; FE, multifocal PR | VA 0.0; SLE, AV cells; FE, multifocal PR and peripheral large FNR | Multiple recurrences OU; months 11, 21, and 24, active peripheral lesions; month 27, active peripheral lesion OS | Month 21, epiretinal membrane OD; month 27, rhegmatogenous RD OS | 36; 0.0 OD, 0.8 OS |
| 48/M† |
Bilateral |
VA 2.1; SL, EAV cells; FE, macular FNR |
VA 0.3; SLE, AV cells;
FE, peripheral FNR |
2 recurrences OS; new peripheral scar in months 12 and 15 |
Month 9, epiretinal membrane OD; month 34, epiretinal membrane OS |
34; 1.9 OD, 0.4 OS |
| 43/M† |
Unilateral |
VA 0.0; SLE, normal; FE, Leber miliary aneurysms |
VA 0.7; SLE, fine KP, AC cells 2+/4+, and AV cells; FE, peripheral large FNR |
─ |
None |
36; 0.1 OS |
| 27/M |
Unilateral |
VA 0.0; SLE, AV cells; FE, PR |
VA 0.0; normal SLE and FE |
─ |
None |
23; 0.0 OD |
| 42/M† |
Unilateral |
VA 0.5; SLE, granulomatous KP, AC cells (3+/4+), AV cells; IOP, 28 mmHg; FE, peripheral large FNR |
VA 0.0; normal SLE and FE |
1 recurrence OD; month 9, multiple active peripheral lesions OD |
Baseline transient IOP elevation OD, 28mmHg |
24; 0.0 OD |
| 31/M |
Unilateral |
VA 0.0; normal SLE and FE |
VA 0.0; SLE OS, AV cells; FE, multiple peripheral FNR |
─ |
None |
8; 0.0 OS |
| 50/M† |
Unilateral |
VA 0.5; SLE, AV cells;
FE, peripheral large FNR |
VA 0.0; normal SLE and FE |
─ |
Month 6, posterior vitreous detachment OD |
37; 0.0 OD |
| 47/F† |
Unilateral |
VA 1.6; SLE, AV cells; FE, macular FNR |
VA 0.0; normal SLE and FE |
─ |
None |
37; 1.9 OD |
| 40/M† |
Unilateral |
VA 0.0; SLE, AV cells; FE, peripheral large FNR |
VA 0.0; normal SLE and FE |
─ |
None |
37; 0.0 OD |
| 45/M |
Unilateral |
VA 0.0; SLE, AV cells; FE, PR |
VA 0.0; normal SLE and FE |
─ |
None |
37; 0.0 OD |
| 15/M‡ |
NA |
VA 0.0; normal SLE and FE |
VA 0.0; normal SLE and FE |
Late ocular involvement; OD VA 0.1; month 34, new peripheral scar |
None |
34; 0.1 OD |
| 28/F‡ | NA | VA 0.0; normal SLE and FE | VA 0.0; normal SLE and FE | Late ocular involvement; OD VA 0.0; month 37, peripheral FNR | None | 39; 0.0 OD |
*Age represents age at detection of first ocular lesion or scar. AC cells, grading of anterior chamber cells according to Standardization of Uveitis Nomenclature (SUN) working group (29); AV cells, anterior vitreous cells; FE, fundus examination; FNR, focal necrotizing retinochoroiditis, large FNR is >3 disk diameters; IOP, intraocular pressure; KP, keratic precipitates; NA, not applicable; OD, oculus dexter (right eye); OS, oculus sinister (left eye); OU, oculus uterque (both eyes); PR, punctate retinochoroiditis; RC, retinochoroiditis; RD, retinal detachment; SLE, slit-lamp examination; VA, visual acuity (log MAR); –, no recurrence or no new lesion. †Patients with severe ocular involvement, including binocular, macular, or extensive necrotizing retinochoroiditis (>3 disk diameters). ‡Patients with initial normal ophthalmic examination.